cempra inc (CEMP) Details

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to treat drug-resistant bacterial infections in the community and hospital. The company develops solithromycin in oral and intravenous formulations for the treatment of respiratory tract infections, including community acquired bacterial pneumonia (CABP) and bacterial urethritis comprising gonorrhea. Its solithromycin product candidate is in Phase III clinical trial for the treatment of CABP. The company also develops Taksta, an oral therapy for the long term treatment of prosthetic joint infections caused by staphylococci. Its Taksta product candidate has completed a Phase II clinical trial in patients with acute bacterial skin and skin structure infections; and is in Phase II clinical trial for the treatment of prosthetic joint infections. In addition, the company intends to use its series of proprietary lead compounds for the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. Cempra, Inc. has collaborative research and development, and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

cempra inc (CEMP) Top Compensated Officers